青少年使用大麻前后精神病谱系症状的变化
该队列研究利用ABCD研究5个波次、4年随访数据,纳入11858名基线9-10岁青少年,采用不连续生长曲线模型分析大麻使用前后精神病谱系症状轨迹。结果显示,使用大麻者报告更多精神病谱系症状及痛苦,且症状在大麻使用前已上升,支持共享易感性与自我用药假说,而使用后症状增加证据不一致。
要点
- 使用大麻的青少年精神病谱系症状数量更多(B=0.86)且痛苦更高(B=1.17),支持共享易感性假说。
- 大麻使用前,精神病谱系症状数量(B=0.16)和痛苦(B=0.23)随时间增加,支持自我用药假说。
- 大麻使用后精神病症状增加证据不一致,对促成风险假说支持有限。
核心结论
- 建模大麻-精神病风险关联时,应考虑共享易感性和自我用药效应。
研究设计与样本
- 队列研究,使用ABCD研究5个波次、4年随访数据,来自美国21个研究站点,基线纳入11868名9-10岁青少年,排除3名缺失数据者,最终分析11858人。
- 采用不连续生长曲线模型评估大麻使用前后精神病谱系症状轨迹,控制变量包括年龄、性别、内化与外化症状、社会经济地位、父母心理健康及其他物质使用。
主要发现
- 研究期间任何时间使用大麻的青少年较从未使用者报告更多精神病谱系症状(B=0.86;95%CI 0.68-1.04)和更多痛苦(B=1.17;95%CI 0.96-1.39)。
- 大麻使用前,精神病谱系症状数量(B=0.16;95%CI 0.12-0.20)和痛苦(B=0.23;95%CI 0.21-0.26)随时间增加。
- 大麻使用后精神病症状增加证据不一致。
关键数值与推荐
- 共享易感性假说:使用大麻者较从未使用者症状数量B=0.86(95%CI 0.68-1.04),痛苦B=1.17(95%CI 0.96-1.39)。
- 自我用药假说:使用前症状数量B=0.16(95%CI 0.12-0.20),痛苦B=0.23(95%CI 0.21-0.26)。
- 促成风险假说:使用后症状增加证据不一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adolescent cannabis use has been consistently posited to contribute to the onset and progression of psychosis. However, alternative causal models may account for observed associations between cannabis use and psychosis risk, including shared vulnerability for both cannabis use and psychosis or efforts to self-medicate distress from psychosis spectrum symptomology. OBJECTIVE: To test 3 hypotheses that may explain cannabis-psychosis risk associations by modeling psychosis spectrum symptom trajectories prior to and after cannabis initiation across adolescent development (approximately 10-15 years of age). DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from 5 waves across 4 years of follow-up from the Adolescent Brain Cognitive Development (ABCD) Study. The ABCD study is an ongoing large-scale, longitudinal study of brain development and mental and physical health of children in the US launched in June 2016. Data are collected from 21 research sites. The study included data from 11 868 adolescents aged 9 to 10 years at baseline. Three participants were excluded from the present analysis owing to missing data. Data analysis was performed from September 2023 to July 2024. MAIN OUTCOMES AND MEASURES: Discontinuous growth curve modeling was used to assess trajectories of psychosis spectrum symptoms before and after cannabis initiation. Control variables considered for this investigation were age, sex, internalizing and externalizing symptoms, socioeconomic status, parental mental health, and other substance use. RESULTS: Among the 11 858 participants at wave 1, the mean (SD) age was 9.5 (0.5) years; 6182 (52%) participants were male. Consistent with a shared vulnerability hypothesis, adolescents who used cannabis at any point during the study period reported a greater number of psychosis spectrum symptoms (B, 0.86; 95% CI, 0.68-1.04) and more distress (B, 1.17; 95% CI, 0.96-1.39) from psychosis spectrum symptoms relative to those who never used cannabis. Additionally, consistent with a self-medication hypothesis, the number of psychosis spectrum symptoms (B, 0.16; 95% CI, 0.12-0.20) and distress (B, 0.23; 95% CI, 0.21-0.26) from psychosis spectrum symptoms increased in the time leading up to cannabis initiation. We observed mixed evidence for an increase in psychosis symptoms after cannabis initiation (ie, contributing risk hypothesis). CONCLUSION AND RELEVANCE: The findings underscore the importance of accounting for shared vulnerability and self-medication effects when modeling cannabis-psychosis risk associations.
引用
- Osborne KJ, Barch DM, Jackson JJ, et al. Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation. JAMA Psychiatry. 2025. PMID: 39504015. doi:10.1001/jamapsychiatry.2024.3525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。